Pain News and Research

Latest Pain News and Research

Nutra Pharma to launch prescription analgesic for severe chronic pain treatment

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain.

7 Oct 2009

Electrostimulation techniques for osteoarthritis still unclear

Despite twenty years of research on the use of electrostimulation techniques (TENS) for treatment of osteoarthritis in the knee, researchers still cannot say whether it reduces pain or physical disability. This is the conclusion of a Cochrane Systematic Review of electrostimulation trials in osteoarthritis

7 Oct 2009

Transenterix raises $55 million to manufacture and market its revolutionary laparoscopic surgical platform

TransEnterix Inc. has secured $55 million in a second round of institutional financing, paving the way for the company to manufacture and market its revolutionary laparoscopic surgical platform.

7 Oct 2009

Free educational brochure on physical therapy

Physiotherapy Associates, the nation's foremost provider of outpatient rehabilitation services, today announced that a free educational brochure on the benefits of physical therapy is available to celebrate October as "National Physical Therapy Month," as designated by the American Physical Therapy Association.

7 Oct 2009

More studies needed to compare the efficacy of different biologic drugs for RA, say researchers

More studies that directly compare the effectiveness of different biologic drugs for rheumatoid arthritis (RA) are needed, say Cochrane Researchers. The researchers reviewed all previous Cochrane Systematic Reviews assessing the effectiveness of biologic disease-modifying drugs for treatment of RA and found that although all were very effective, there was little data on direct comparisons between the drugs that could help doctors decide which to prescribe.

7 Oct 2009

Opioid drugs may not be effective for osteoarthritis

Should you take opioid drugs for hip and knee pain caused by osteoarthritis? Probably not, suggests a new review of the best research on the subject.

7 Oct 2009

Cochrane Systematic Review finds Abatacept effective against rheumatoid arthritis

Abatacept, a member of a new class of drug that targets immune cells to treat rheumatoid arthritis (RA), is effective against RA, according to a new Cochrane Systematic Review. The review examines recent trials to assess safety and efficacy of the drug.

7 Oct 2009

New ultrasound probe effective for treating kidney stones

A relatively new ultrasound probe procedure has the highest success rate for breaking down kidney stones in the lower "funnel" area of the kidney, rather than the shock wave treatment used for many years, according to a review of studies.

7 Oct 2009

Research must focus on discovering potential causes and treatments for Bell's palsy

Drugs widely prescribed to treat facial paralysis in Bell's palsy are ineffective and are based on false notions of the cause of the condition, according to Cochrane Researchers. They say research must now focus on discovering other potential causes and treatments.

7 Oct 2009

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Data results published this month in Clinical Neuropharmacology, revealed that Merz Pharmaceuticals' NT 201 (botulinum toxin type A free from complexing proteins), also known by the brand name Xeomin in Europe and Canada, was statistically significantly more efficacious than placebo for the treatment of patients with post-stroke upper limb spasticity.

7 Oct 2009

Aerobic and strength training exercises safe and effective for rheumatoid arthritis patients

Exercise programs designed to improve strength and stamina are safe and effective treatments for rheumatoid arthritis (RA), according to a new Cochrane Systematic Review.

7 Oct 2009

940nm wavelength laser is superior for treating facial spider veins: BUSM researchers

Researchers from Boston University School of Medicine (BUSM) have concluded that the 940nm wavelength laser is superior for treating facial spider veins (telangiectasias) as compared to the 532nm wavelength laser. The findings, which appear in the recent issue of Lasers in Surgery and Medicine, are the first time these lasers were tested against each other for superiority.

7 Oct 2009

Phase 2 clinical study results of TOPICA's luliconazole for athlete's foot announced

TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced positive results from its Phase 2 clinical study evaluating luliconazole, one of the most potent and broad spectrum topical antifungal agents, in patients with tinea pedis (athlete's foot). The study was designed to assess the effectiveness of 1% luliconazole cream applied once daily for 14 days compared with once daily for 28 days.

6 Oct 2009

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

AVANIR Pharmaceuticals, Inc. today announced it will present detailed data from the Phase III confirmatory STAR trial in the treatment of pseudobulbar affect (PBA) at the 3rd World Congress on Controversies in Neurology (CONy) in Prague, Czech Republic on October 8 - 11, 2009 and the American Neurological Association (ANA) 134th Annual Meeting in Baltimore, MD on October 11 - 14, 2009.

6 Oct 2009

Phase 3 results of Transdel's lead topical pain drug Ketotransdel announced

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced positive top-line clinical results for its lead pain drug Ketotransdel®( )in a Phase 3 trial which evaluated the efficacy and safety of the drug in acute soft tissue injuries of the upper and lower extremities.

6 Oct 2009

Vantia Therapeutics announces the start of Phase II proof-of-concept trials of its VA111913 drug

Vantia Therapeutics today announces that its novel oral small molecule drug for the treatment of dysmenorrhoea (painful menstruation) has entered Phase II proof-of-concept trials. In addition, Vantia announces results of the successful Phase I trial of VA111913, which showed the product candidate to be safe and well tolerated.

6 Oct 2009

16 Canadian students living with chronic illness to receive UCBeyond Scholarships

What would you do if you were faced with a chronic illness? Would you walk across Canada to raise awareness for Crohn's disease, build houses in developing countries despite physical pain or dedicate your career to educating young people living with the same disease as you?

6 Oct 2009

Sosei R&D enters agreement with Pharmasol R&D to assign its rights to the assets of AD 923

Sosei Group Corporation, the biopharmaceutical company, today announced that Sosei R&D Ltd., its wholly owned UK subsidiary, has entered into an agreement to assign its rights to the assets of AD 923, an optimised, sublingual formulation of the opioid analgesic fentanyl for the treatment of cancer breakthrough pain, as well as to the device for drug administration to Pharmasol R&D Ltd., a privately held UK company.

6 Oct 2009

AAAHC accreditation for Laser Spine Institute Tampa

Laser Spine Institute, leaders in minimally invasive spinal surgery, is pleased to announce the accreditation of LSI Tampa by the Accreditation Association for Ambulatory Health Care.

6 Oct 2009

FDA accepts ProStrakan's Abstral NDA filing for review

Orexo AB (STO:ORX) today confirms that its partner, ProStrakan Group plc (LSE: PSK), has announced that the New Drug Application (NDA) filing for Abstral has been accepted for review by the US Food and Drug Administration (FDA).

6 Oct 2009

Pain News and Research

Latest Pain News and Research

Nutra Pharma to launch prescription analgesic for severe chronic pain treatment

Electrostimulation techniques for osteoarthritis still unclear

Transenterix raises $55 million to manufacture and market its revolutionary laparoscopic surgical platform

Free educational brochure on physical therapy

More studies needed to compare the efficacy of different biologic drugs for RA, say researchers

Opioid drugs may not be effective for osteoarthritis

Cochrane Systematic Review finds Abatacept effective against rheumatoid arthritis

New ultrasound probe effective for treating kidney stones

Research must focus on discovering potential causes and treatments for Bell's palsy

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Aerobic and strength training exercises safe and effective for rheumatoid arthritis patients

940nm wavelength laser is superior for treating facial spider veins: BUSM researchers

Phase 2 clinical study results of TOPICA's luliconazole for athlete's foot announced

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

Phase 3 results of Transdel's lead topical pain drug Ketotransdel announced

Vantia Therapeutics announces the start of Phase II proof-of-concept trials of its VA111913 drug

16 Canadian students living with chronic illness to receive UCBeyond Scholarships

Sosei R&D enters agreement with Pharmasol R&D to assign its rights to the assets of AD 923

AAAHC accreditation for Laser Spine Institute Tampa

FDA accepts ProStrakan's Abstral NDA filing for review

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Pain News and Research

Latest Pain News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in